Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease
Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease
复制标题
先天性心脏病继发性肺动脉高压患者血清 HMGB1 升高
DOI：
10.1016/j.vph.2016.08.009
复制
发表时间：
2016-10-01
影响因子：
4
通讯作者：
Li, Jiang
中科院分区：
文献类型：
--
作者：
Huang, Yi-yuan;Su, Wei;Li, Jiang
目的：本研究旨在探讨血清高迁移率族蛋白1（HMGB1）水平在先天性心脏病继发肺动脉高压（PAH-CHD）患者诊断、分期及治疗反应中的潜在价值。采用酶联免疫吸附法测定血清HMGB1水平。PAH组HMGB1水平显著高于非PAH组（P <0.01）和健康对照组（P <0.001）。HMGB1水平与肺动脉压（P <0.001）和肺血管阻力（P <0.001）显著相关。在重度PAH患者中，艾森曼格综合征（ES）患者的HMGB1水平显著高于低PVR患者（P <0.001）。以血清HMGB1作为判断重度PAH和ES的临界值，分别为13.62 ng/mL（P <0.001）和21.62 ng/mL（P = 0.001），其特异性和敏感性分别为82.8%和90%;结论：血清HMGB1水平可作为CHD患者PAH的生物标志物，可用于评估肺血管重构和评价西地那非的疗效。(C)2016 Elsevier Inc. All rights reserved.
Aims: This study investigated the potential value of serum high mobility group box-1 (HMGB1) level in the diagnosis, staging and treatment response of patients with pulmonary arterial hypertension secondary to congenital heart disease (PAH-CHD).Methods and results: This was a single-center prospective study in 106 CHD patients. Serum HMGB1 levels were measured by enzymelinked immunosorbent assay. HMGB1 levels were significantly increased in patients with PAH compared to patients without PAH (P < 0.01) and healthy controls (P < 0.001). HMGB1 levels significantly correlated with pulmonary arterial pressure (P < 0.001) and pulmonary vascular resistance (PVR) (P < 0.001). In patients with severe PAH, HMGB1 levels were significantly higher in patients with Eisenmenger syndrome (ES) than in patients exhibiting low PVR (P < 0.001). Severe PAH and ES was identified by serum HMGB1 with a cutoff value of 13.62 ng/mL (P < 0.001) with a specificity of 82.8% and a sensitivity of 90%, and a cutoff value of 21.62 ng/mL (P = 0.001) with a specificity of 85.2% and a sensitivity of 64.3%, respectively. HMGB1 levels were significantly decreased after sildenafil therapy for 6 months (P < 0.01).Conclusions: Our study suggests that serum HMGB1 level may be used as a biomarker to identify PAH in CHD patients, assess pulmonary vascular remodeling, and evaluate the treatment response to sildenafil. (C) 2016 Elsevier Inc. All rights reserved.